Trial Profile
A Multicentre, Non-interventional Post Marketing Study of Safety and Efficacy of NovoEight (rFVIII) During Long-Term Treatment of Haemophilia A in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2021
Price :
$35
*
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 03 Mar 2021 Status changed from active, no longer recruiting to completed.
- 05 Jun 2019 Planned number of patients changed from 35 to 40.
- 05 Jun 2019 Status changed from recruiting to active, no longer recruiting.